BAM15
Aliases: BAM-15
Last verified: 2026-09-23
The short version
A mitochondrial uncoupler — dissipates the proton gradient → increased energy expenditure without DNP-like hyperthermia. A potential safer successor to DNP (preclinical). Key fact: No controlled human trials exist. Everything known about BAM15 in humans comes from indirect sources and self-reports. Status: preclinical. Not approved; research only.
Identity & type
- Molecular type
- mali molekul
- Origin
- A mitochondrial uncoupler — dissipates the proton gradient → increased energy expenditure without DNP-like hyperthermia.
Mechanism of action
Mild uncoupling → thermogenesis and fat oxidation without full collapse of ATP synthesis.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for BAM15. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Preclinical only. No human experiences; the community follows development as a potentially "safer DNP".
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
No human experiences; the community follows development as a potentially "safer DNP".
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
No controlled human trials exist. Everything known about BAM15 in humans comes from indirect sources and self-reports.
Preclinical evidence
Preclinical obesity studies (Virginia Tech).
Known risks
- Unknown in humans.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- All human pharmacokinetics, safety and efficacy
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.